Sarepta Therapeutics, Inc. - Common Stock · Transaction Apr 14, 2025 · Filed May 6, 2025 · $1,001 to $15,000
NASDAQ NMS - GLOBAL MARKET · SRPT
-3.14% · -$0.6500 · Vol 6.3M
Market closed · last close 4:00 PM ET · price as of 19:00:03 ET
Sarepta Therapeutics Inc
Biotechnology
$20.02
Follow $SRPT
One email when a member of Congress discloses a trade in it, with the official filing receipt linked.
Free. No account. Unsubscribe in one click.
Follow $SRPT by emailVeridion Score
BETAHIGH CONF · 6 of 6 factors measuredSat Sep 19 · market closed · Markets closed · resumes Mon 9:30 ET · SRPT
MethodologySRPT
Sarepta Therapeutics Inc
Sat Sep 19 · market closed · Markets closed · resumes Mon 9:30 ET
Upper range
Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.
Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
64/ 100
Veridion Score
Upper range · HIGH confidence · 6 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: HIGH · 6 of 6 factors measured · Sat Sep 19 · market closed · Markets closed · resumes Mon 9:30 ET
Veridion Score History · 90D
Loading score history
AI Analysis
SovereignWhy is SRPT moving today?
Sovereign unlock connects news, insider activity, analyst moves, and live price action.
About Sarepta Therapeutics Inc
PHARMACEUTICAL PREPARATIONSListed since
1997
Employees
835
Country
US
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.
Key statistics
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Open
$20.63
Day high
$20.74
Day low
$19.62
Previous close
$20.67
52W high
$24.45
-18.12% from high
52W low
$14.86
54% of range
Market cap
$2.1B
P/E
4.74×
EPS
$4.22
Beta
1.15
Shares out
105.6M
Volume
6.3M
2.06× rel vol
Avg volume
3M
VWAP
$20.07
Price history computed in-house
1W
-2.10%
1M
+4.16%
3M
+14.20%
1Y
+14.86%
YTD
-6.97%
SMA 50 $18.55 · above
SMA 200 $19.27 · above
52W position 54%
SRPT overview
Related filings and maps
Public disclosures
Congress activity in SRPT
Official filing ↗
Gilbert CisnerosSell
SRPT · Transaction Apr 14, 2025 · Filed May 6, 2025 · $1,001 to $15,000
Sarepta Therapeutics, Inc. · Transaction Jul 14, 2023 · Filed Aug 21, 2023 · $1,001 to $15,000
Sarepta Therapeutics, Inc. · Transaction Jun 13, 2023 · Filed Jul 11, 2023 · $1,001 to $15,000
Daniel GoldmanSell
SRPT · Transaction Apr 10, 2023 · Filed May 19, 2023 · $15,001 to $50,000
Federal contracts
SRPT contract awards, year to date.
Public federal awards linked to this ticker.
Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for SRPT in this window.
Lobbying spend
SRPT lobbying filings, year to date.
Registered lobbying filings matched to Sarepta Therapeutics Inc.
Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for SRPT in this window.
Analyst ratings
Sovereign unlock shows live analyst consensus for SRPT.
Options
Sovereign unlock shows live options positioning for SRPT.